Created in 2006 as a spin-off from bioMérieux, GeNeuro is a Swiss biopharmaceutical company. GeNeuro raised approximatively EUR 33 million through its IPO. The proceeds will be used to strengthen GeNeuro’s capital structure and finance its work on multiple sclerosis and new autoimmune indications as well as its growth in Europe and the United States.
BNP Paribas Securities Services provided management and administration services for the new shares issuance by simplifying and securing the different processes.
Post-IPO, BNP Paribas Securities Services is acting as GeNeuro’s information agent, keeping market participants up to date with any changes in the structure of GeNeuro’s capital, and will also provide GeNeuro with dividend payment services.
“We thank BNP Paribas Securities Services for its proactive and effective approach to this IPO, in particular in terms of navigating the complexities of this first listing of a Swiss company on Euronext Paris. We are very satisfied with the choice we made,” said Miguel Payró, Chief Financial Officer of GeNeuro.
Pierre Jond, Head of Corporate Trust Services at BNP Paribas Securities Services said: "We are delighted to have successfully completed this listing of an international life science company, the first major listing in Paris in 2016.”
About BNP Paribas Securities Services (www.bnpparibas.com)
BNP Paribas Securities Services, a wholly-owned subsidiary of the BNP Paribas Group, is a leading global custodian and securities services provider backed by the strength of the BNP Paribas Group. It provides multi asset post trade and asset servicing solutions for institutional participants in the investment cycle, from the buy-side and sell-side to corporates and issuers. Covering over 100 markets, offices in 34 countries, the BNP Paribas network is one of the most extensive in the industry. We bring together local insight and a global network to enable clients to maximize their market and investment opportunities worldwide.
BNP Paribas Securities Services on Twitter - @BNPP2S